ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
-
Published:2021-11-08
Issue:16
Volume:22
Page:1832-1843
-
ISSN:1389-4501
-
Container-title:Current Drug Targets
-
language:en
-
Short-container-title:CDT
Author:
Li Shuainan1,
Ma Wenya1,
Yang Fan1,
Xu Yan1,
Xu Binbin1,
Cai Benzhi1
Affiliation:
1. Department of Pharmacy at the Second Affiliated Hospital, and Department of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, China
Abstract
ACE2 has long been known as an injury protective protein, which can protect against a
variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases,
as a negative regulator of RAAS, ACE2 is an extremely important protective factor that
mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of
COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2,
which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is
found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and
SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms.
Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and
cardiovascular diseases/heart injury.
Funder
Natural Science Foundation of Heilongjiang Province
China Postdoctoral Science Foundation
National Natural Science Fund of China
National Key R&D Program of China
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine